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Harmonizing Race: 
    Competing Regulatory 
    Paradigms of  
    Racial Categorization in 
    International Drug 
    Development 
Jonathan Kahn, J.D., Ph.D∗ 
I.  Introduction 
Two powerful dynamics are at the forefront of contemporary pharmaceutical 
development: global outsourcing of clinical trials and pharmacogenomics.  These 
two dynamics come together in the regulatory arena through the development of 
international guidelines to harmonize the production and use of clinical data 
involving diverse ethnic and racial groups.  Such guidelines both produce and are 
produced by the drive to develop individually tailored medicines in a world 
market.  While promulgated to promote more efficient pharmaceutical 
development, such mandates may also have the unintended consequence of 
reshaping cultural and ultimately legal understandings of race and ethnicity as 
genetically distinct and bounded categories.  The regulatory construction of race 
and ethnicity as genetic has the potential to produce both skewed science and 
discriminatory social policies. 
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This article will examine the implications of U.S. federal and international 
regulatory mandates in the construction and circulation of racial categories in 
biomedical research and drug development.  It will focus on the interface between 
two regulatory mandates in particular: the International Conference on 
Harmonization (ICH) Guideline Document E-5 on “Ethnic Factors in the 
Acceptability of Foreign Clinical Data,”1 and the U.S. Food and Drug 
Administration (FDA) “Guidance for Industry: Collection of Race and Ethnicity 
Data in Clinical Trials.”2  The ostensible purpose of both of these guidelines is to 
promote more efficient and economical development of new pharmaceutical 
interventions.  Underlying both Guidances is a presumption that race and ethnicity 
are relevant variables in assessing the safety and efficacy of drugs in clinical trials.  
Both Guidances also implicitly cast race and ethnicity as obstacles to be managed 
and overcome in the course of getting new drugs to global markets as quickly and 
cheaply as possible. 
Ultimately, however, the Guidances are driven by different regulatory 
considerations which place them in tension with one another.  The ICH guideline’s 
primarily concern is to “harmonize” different state regulatory regimes in the 
international arena.  Its goal is to enable clinical data produced in one jurisdiction 
to be used in another jurisdiction for the purposes of drug registration.3  The FDA 
guideline is primarily concerned with providing a standardized bureaucratic 
classification for racial and ethnic categories such that clinical trial data can be 
collected and reported in a consistent manner within the FDA’s jurisdiction.4  The 
FDA, therefore, adopts the racial and ethnic categories promulgated by the U.S. 
Office of Management and Budget – used most familiarly in the U.S. Census.5  
These categories, the FDA notes, “were developed in response to the need to 
enforce civil rights laws in education” and should “not be interpreted as being 
scientific or anthropological in nature.”  The FDA categories are therefore 
theoretically to be understood as social not genetic in nature.  The ICH E5 
Guideline does not set forth particular ethnic categories per se, but rather 
 
 1. International Conference on Harmonization, Ethnic Factors in the Acceptability of Foreign 
Clinical Data, (Feb. 5, 1998), available at  http://www.ich.org/LOB/media/MEDIA481.pdf 
[hereinafter ICH E5]. 
 2. U.S. Food and Drug Administration (FDA), Guidance for Industry:  Collection of Race and 
Ethnicity Data in Clinical Trials (2005), available at 
http://www.fda.gov/cder/guidance/5656fnl.pdf [hereinafter FDA Guidance]. 
 3. ICH E5, supra note 1, at 1. 
 4. FDA Guidance, supra note 2, at 1. 
 5. Id. at 3. 
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elaborates a series of “ethnic factors” which include social/cultural practices, 
physiological processes, and genetics which are posited as potential variants across 
ethnic groups. 
The ICH process is transforming global drug development and marketing, and, 
in particular, is opening up the large Japanese market to pharmaceuticals tested in 
the West.  The FDA Guidance similarly promises to transform the production and 
organization of racial and ethnic data in clinical trials for the U.S. market.  As 
pharmaceutical development goes global, however, the social classifications of the 
FDA Guidance also promise to collide with the mixture of social, physiological 
and genetic “factors” elaborated in the ICH guideline.  These diverse classificatory 
schemes cannot be easily reconciled.  This paper will explore how concepts of race 
and ethnicity are being produced and reproduced through this collision.  It will 
further explore how these distinct attempts to “regulate race” in a bureaucratic 
context are shaping the development of global pharmaceutical markets. 
Part II of the article will set forth the background to the ICH E5 regulatory 
mandate and its distinct concepts of race and ethnicity.  Part III will explore how 
the ICH guidelines have already begun to affect global pharmaceutical 
development.  Part IV will set forth the background to the FDA guidelines on the 
collection of racial and ethnic data for clinical trials.  It will then go on to examine 
the debates that arose around the adoption of the FDA guidelines, specifically as 
they involved considerations of how the FDA guidelines might impact global 
pharmaceutical development under the ICH regulatory regime.  Part V will 
conclude the article with an examination of the broader implications of this story 
for the production of social and regulatory understandings of the nature of race and 
ethnicity. 
II.  Background to the ICH E5 Guidelines 
A.  The ICH 
The ICH, formally known as the International Conference on Harmonization of 
Technical Requirements for Registration of Pharmaceuticals for Human Use, was 
formed in 1990 at a meeting in Brussels hosted by the European Federation of 
Pharmaceutical Industries and Associations (EFPIA).6  Interested parties at the 
meeting included representatives of the regulatory agencies and industry 
 
 6. ICH, History and Future of ICH, http://www.ich.org/cache/compo/276-254-1.html  
 (last visited May 16, 2006). 
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associations of Europe, Japan, and the USA.7  The formation of the ICH was born 
out of concerns “over rising costs of health care, escalation of the cost of R&D 
[Research & Development] and the need to meet the public expectation that there 
should be a minimum of delay in making safe and efficacious new treatments 
available to patients in need.”8  One underlying factor affecting all of these 
concerns was the diverse regulatory standards imposed by the governments of the 
major pharmaceutical markets in the US, the European Union (EU), and Japan.  
Founding members believed that the harmonization of standards for product 
development and regulatory approval would greatly increase the efficiency and 
economy of drug development and pave the way for the creation of a truly global 
pharmaceuticals market.9  More specifically, harmonization was seen as a means to 
lower drug development costs, reduce the time necessary to bring new drugs to 
new markets, improve regulatory efficiency, and minimize risks to research 
subjects.10 
The ICH is structured around the US, the EU, and Japan. These regions account 
for approximately 80% of the global pharmaceutical market.11  By region, the 
founding members were: US – the FDA and the Pharmaceutical Research and  
Manufacturers of America (PhRMA), which represents the leading research-based 
pharmaceutical and biotechnology companies in the United States; the EU – the 
European Commission (representing the twenty-five members of the EU) and the 
EFPIA, which is composed of twenty-five national pharmaceutical industry 
associations (plus six associations with liaison status) and forty-three leading 
pharmaceutical companies involved in the research, development and 
manufacturing of medicinal products in Europe for human use; Japan – the 
Ministry of Health, Labor and Welfare (MHLW) and the Japan Pharmaceutical 
Manufacturers Association (JPMA), which represents ninety member companies 
including all the major research-based pharmaceutical manufacturers in Japan.12  
These groups play the primary role in ICH decision making.13  Additionally, there 
 
 7. Id. 
 8. Id. 
 9. Id. 
 10. J. John Lee, Comment: What is Past is Prologue: The International Conference on 
Harmonization and Lessons Learned from European Drug Regulations Harmonization,  
 26 U. PA. J. INT’L ECON. L. 151,155 (2005). 
 11. Carly Anderson et al., Bridging Studies in Asia and the Impact of the ICH E5 Guideline, 37 
DRUG INFORMATION J. 107S (2003). 
 12. Id. 
 13. Id. 
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are three observer organizations, the World Health Organization (WHO), Health 
Canada, and the European Free Trade Association (EFTA) who nominate non-
voting participants to attend the ICH Steering Committee Meetings.14 
B.  ICH E5 
Since its inception, the ICH has promulgated a series of “Guidelines” grouped 
into three broad categories: Quality, Safety, and Efficacy.  Additionally, the ICH 
has adopted a “Common Technical Document” (CTD)15 which serves as a standard 
form for drug licensing approval across all three ICH regions.16  A key 
consideration for global drug development and registration involves the 
acceptability of data in different regions.  To address this issue, the ICH adopted 
Guideline E5, “Ethnic Factors in the Acceptability of Foreign Clinical Data,” in 
1998.17  ICH E5 is intended to facilitate drug registration in the different ICH 
regions by recommending a framework for evaluating the impact of ethnic factors 
on a drug’s safety and efficacy in a manner that will enable appropriate evaluation 
of ethnic factors.  The Guideline is premised on the “desirability of utilizing 
foreign clinical data that meet the regulatory standards and clinical trial practices 
acceptable to the region considering the application for registration.”18 
In recent decades, ethnicity has become perceived as a barrier to the 
globalization of pharmaceutical development and marketing.  Japan, in particular, 
has resisted the licensing of many drugs already licensed in the US and the EU on 
the grounds that clinical data based on studies of safety and efficacy conducted in 
“Caucasian” populations cannot be directly extrapolated to apply to the “Japanese” 
population.19  As one senior Japanese hospital official put it: 
Ethnic factors in a broad sense have been regarded as one of the unavoidable reasons to 
have some barriers to the acceptance of foreign clinical data.  Therefore, the problem of 
“Ethnic Factors in the Acceptability of Foreign Clinical Data” has been regarded as a 
difficult, but the most important, subject in the harmonization of the clinical field of 
ICH.20 
 
 14. Id. 
 15. ICH, Common Technical Document, http://www.ich.org/cache/compo/276-254-1.html  
 (last visited May 18, 2006). 
 16. Lee, supra note 10, at 180. 
 17. ICH E5, supra note 1, at 1. 
 18. Id. 
 19. Anderson, supra note 11. 
 20. Chikayuki Naito, Ethnic Factors in the Acceptability of Foreign Clinical Data, 32 DRUG 
INFORMATION J. 1283S (1998), available at 
http://diahome.org/content/abstract/1998/dijs1227.pdf. 
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A driving concern behind the development of ICH E5, therefore, was to allow 
data from clinical trials conducted in the “predominantly Caucasian” patient 
population of the West to be extrapolated to the population of Japan.21  Japan has 
the second largest national drug market in the world22 but it has been historically 
difficult for Western pharmaceutical companies to gain entry to the Japanese 
market for drugs tested in the West.23  Japanese regulatory authorities have resisted 
approving such drugs on grounds that they may work differently in Japanese 
populations.24  Thus, for example, of the 149 drugs approved by the US FDA 
between 1992 and 1996 (before ICH E5 was adopted in 1998), 51% were not 
available to patients in Japan by 2000.25 
A major objective of ICH E5 is to allow for the extrapolation of data produced 
in one ICH region to a different region.26  It is hoped that providing a regulated 
framework for such extrapolation will minimize the duplication of clinical data and 
facilitate the acceptance of foreign clinical data in new regions.27  ICH E5 also 
describes a mechanism known as “bridging studies” which allows for the use of 
smaller, cheaper studies in a host region’s population as a basis for extrapolating 
data from larger full-scale clinical studies about which the host region otherwise 
has reservations.28  Bridging studies thus supplement existing data as basis for 
extrapolation, in effect leveraging existing data into new regulatory regimes. 
It is in relation to bridging studies that so-called “Ethnic Factors” become most 
salient.  ICH E5 is premised on the idea that it should not be necessary to repeat an 
entire clinical drug development program in a new region.29  It provides for the 
development of a “clinical data package” that would fulfill the regulatory 
requirements of a new region based on data produced in the originating region.30  
At this point, the only remaining barrier to acceptance would be the concerns of 
 
 21. Anderson, supra note 11. 
 22. Stanford Jhee and Edyta Frackiewiewicz, Bridging Strategies May Help Put Western Drugs 
on the Japanese Market, APPLIED CLINICAL TRIALS, Sept. 1, 2003, 
http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=79907. 
 23. Carly Anderson and Faiz Kermani, Global Acceptability of Clinical Data –Fact or Fiction?  
http://www.samedanltd.com/members/archives/EPC/Autumn2002/CarlyAnderson.htm, 
(last visited Apr. 16, 2006). 
 24. Id.  See also Jhee and Frackiewiewicz, supra note 22. 
 25. Anderson and Kermani, supra note 23. 
 26. ICH E5, supra note 1, at 2. 
 27. Id. 
 28. Id. at 2, 5. 
 29. Id. at 2. 
 30. Id. at 3. 
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the relevant regulatory authority that “ethnic factors” might impede the 
extrapolation of clinical data produced in one region to apply to the new region.  
The concern here would be that populations from one region might have 
significantly different responses to particular drug, either in terms of safety or 
efficacy, than populations from another region.  ICH E5 therefore both defines the 
parameters of the ethnic factors to be considered in evaluating drug response, and 
provides for conducting smaller “bridging studies” where necessary, to confirm 
relevant safety and efficacy information in the new regions population.31 
Regulatory authorities from the three ICH regions, however, are concerned 
about population-based averages of drug response and the degree to which any 
overall variation might be attributable to ethnic factors.  Responses to any drug 
may vary from individual to individual.  Indeed, for every drug, there are some 
individuals who will respond better or worse or not at all, depending in part on 
their genes.  Some genes also play a substantial role in regulating how the body 
metabolizes as drug.  Finding an optimal dosage for a particular drug may be aided 
by determining whether a particular individual’s genetic profile would lead her to 
metabolize a drug more quickly or slowly than another.32  One irony in the 
promulgation of ICH E5 as a means to overcome regulatory barriers to the 
adoption of new drugs in different regions, especially Japan, are studies showing 
that that intra-ethnic variability in drug response is generally no greater than inter-
ethnic variability.33  Thus, as one study found, 
Even when there may be a statistically significant difference between two or more ethnic 
groups in a given pharmacokinetic parameter of a drug, it is unclear how such difference 
relates to the total population variance in that parameter. In fact, previous surveys of 
potential ethnic differences in pharmacokinetics relevant to drug development and 
registration have suggested that in some cases, interethnic differences appear no larger or 
smaller than intraethnic variations.34 
Another study conducted by the Japanese Ministry of Health and Welfare and 
the Japanese Pharmaceutical Association examining eighty New Chemical Entities 
approved both in Japan and in the West similarly found intraethnic differences 
were greater than interethnic differences.35  Nonetheless, the concept of interethnic 
 
 31. Id. at 3, 5-7. 
 32. B. Evans et al., Creating Incentives for Genomic Research to Improve Targeting of 
Therpies, 10 NATURE MED. 1298 (2004). 
 33. T. Bjornsson et. al., A Review and Assessment of Potential Sources of Ethnic Differences in 
Drug Responsiveness, 43 J. OF CLINICAL PHARMACOLOGY 943, 944 (2003). 
 34. Id. 
 35. Helen Dumitriu, Impact of the ICH Guideline on Ethnic Differences, 32 DRUG 
INFORMATION J.  141, 142 (1998). 
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variation lies at the heart of ICH E5 and of the subsequent development of a new 
industry in bridging studies that has emerged in order to facilitate the entry of 
Western drugs into the Japanese market.36 
ICH E5 defines “ethnic factors” as “factors relating to races or large populations 
grouped according to common traits and customs.”37 It makes a further key 
distinction between what it characterizes as “intrinsic” versus “extrinsic” ethnic 
factors.38  It defines “intrinsic ethnic factors” as “factors that help define and 
identify a subpopulation and may influence the ability to extrapolate clinical data 
between regions.  Examples of intrinsic factors include genetic polymorphism, age, 
gender, height, weight, lean body mass, body composition, and organ 
dysfunction.”39  In contrast, it defines “extrinsic ethnic factors” as “factors 
associated with the environment and culture in which a person resides.  Extrinsic 
factors tend to be less genetically and more culturally and behaviorally 
determined.”40  At first blush, this distinction seems straightforward and relatively 
unproblematic.  However, ICH E5 elaborates upon these definitions in a chart 
presented in its appendix in a manner that is far more troubling. 
Specifically, the chart locates race as an intrinsic genetic characteristic.  That is, 
it constructs race as some sort of genetic component of a larger category of 
ethnicity.  Intrinsic ethnicity, in this scheme is presented as encompassing both 
genetic and other broader and more variable biological components, such as age, 
disease and cardiovascular function – each of which can affect the absorption, 
distribution, metabolism and excretion (ADME) of drugs.  Extrinsic ethnicity here 
refers to social, environmental and cultural factors – factors “extrinsic” to the 
physical human organism.  The chart is highly problematic for a number of 
reasons. 
First is the basic definition of what counts as an ethnic and/or racial group.  
Race and ethnicity are not static objective categories.  Rather they have changed 
dramatically over time and across space.  The U.S. Census is a prime example.  
Since the first census in 1790, racial categories have changed over time to reflect 
the social and political concerns of the day.  The first census had four categories: 
Free White Males, Free White Females, Other Free Persons, and Slaves.41  During 
 
 36. Jhee and Frackiewicz, supra note 22. 
 37. ICH E5, supra note 1, at 9. 
 38. Id. at 9-10. 
 39. Id. at 10. 
 40. Id. at 9. 
 41. MELISSA NOBLES, SHADES OF CITIZENSHIP: RACE AND THE CENSUS IN MODERN POLITICS 
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the nineteenth century, additional categories that fell in and out of use included 
Free Colored Persons, Black, Mulatto, Quadroon, Octoroon, Indian, Chinese, and 
Japanese.42  The twentieth century saw a new proliferation of categories including 
Hindu, Korean, and Negro.43 
Second, whatever they are, race and ethnicity are not genetic.  Scientists may 
and do disagree on the utility of using particular racial or ethnic categories as 
surrogates for genetic groupings, arguing about different frequencies of particular 
genetic variations.  But race and ethnicity themselves are not genetically coherent 
concepts.44  Rather, they are best understood as complex and dynamic social 
constructs.45  Indeed, since the 1970s, scientists have understood that race will 
statistically explain only a small portion of human variation.46  As a recent editorial 
in Nature Biotechnology asserted, “[r]ace is simply a poor proxy for the 
environmental and genetic causes of disease or drug response. . . . Pooling people 
in race silos is akin to zoologists grouping raccoons, tigers and okapis on the basis 
that they are all stripey.”47 
Third, as noted above,48 studies conducted largely in response to concerns 
raised by ICH E5 have shown that variation in drug response is often greater within 
ethnic groups, however defined, than across ethnic groups.  This comports 
naturally with the observation made in a 2001 editorial in the journal Nature 
Genetics that, “scientists have long been saying that at the genetic level there is 
more variation between two individuals in the same population than between 
populations and that there is no biological basis for ‘race.’”49 
Fourth, with respect to the specific application of the ICH E5 criteria, one study 
 
28 (2000). 
 42. Id. at 28, 44. 
 43. Id. at 44.  See also generally MARGO ANDERSON, THE AMERICAN CENSUS: A SOCIAL 
HISTORY (Yale University Press 1988); Sandra Soo-Jin Lee et al., The Meaning of ‘Race’ in 
the New Genomics: Implications for Health Disparities Research, 1 YALE J. HEALTH 
POL’Y L. & ETHICS 33 (2001). 
 44. Francis Collins, What We Do and Don’t Know About ‘Race,’ ‘Ethnicity, ’Genetics and 
Health at the Dawn of the Genome Era, 36 NAT. GEN., S13-15 (2004). 
 45. See, e.g., American Anthropological Association, Response to OMB Directive 15: Race and 
Ethnic Standards for Federal Statistics and Administrative Reporting, Sept. 1997, available 
at http://www.aaanet.org/gvt/ombdraft.; American Anthropological Association, Statement 
on Race (1998), available at  http://www.aaanet.org/stmts/racepp.htm [hereinafter AAA, 
Statement]. 
 46. Richard Lewontin, The Apportionment of Human Diversity, 6 EVOL. BIOL. 381, 381-84 
(1972).   
 47. Editorial, Illuminating BiDil, 23 NAT. BIOTECH. 903, 903 (2005). 
 48. See supra text accompanying notes 32-35. 
49. Editorial, Genes, Drugs and Race, 29 NAT. GEN. 239, 239 (2001), available at 
http://www.nature.com/ng/journal/v29/n3/full/ng1101-239.html. 
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noted that “considering the general nature of these guidelines, there is clearly the 
potential for different regions or countries to apply different interpretations, thus 
potentially defeating some of the goals of the guidelines.”50  This is in part because 
the different ethnic groups are not always well characterized, and also because 
even when clearly characterized the definitions often presume more homogeneity 
within the group than is warranted.51 
Finally, in a world rife with historical examples of stigma and discrimination 
based on false constructions of particular groups as biologically different (and/or 
inferior) the geneticization of race is fraught with peril.52  One need not identify 
specific, immediate consequences that might flow directly from the ICH guidelines 
to caution that the formal, regulatory adoption of genetic conceptions of race could 
contribute to unintended and unforeseen negative consequences. 
III.  The Immediate Commercial Impact of ICH E5 
In recent years an entire industry has grown up around global human subject 
recruitment and research for clinical trials in drug development.53  Companies 
known as Contract Research Organizations (CROs) span the globe on behalf of 
Western pharmaceutical corporations looking to outsource clinical trials to more 
economical venues, often in developing nations.54  These foreign sites are 
attractive not only because trials are cheaper, but also because human subjects are 
often easier to recruit, are more deferential to medical authority, and are “treatment 
naïve,” that is, they are not already on other pharmaceutical therapies that might 
mask or interfere with the effect of the drug being tested.55  CROs have become 
big business as the pace of clinical outsourcing has accelerated.  A recent study 
shows that clinical outsourcing has become a significant basis for new growth 
among major pharmaceutical corporations.56 
 
 50. Bjornsonn, supra note 33, at 961. 
 51. Id. at 959-61. 
 52. The literature on this topic is vast and varied.  See generally DANIEL KEVLES, IN THE NAME 
OF EUGENICS (1998); STEPHEN JAY GOULD, THE MISMEASURE OF MAN (1996). 
 53. See generally Adriana Petryna, Ethical Variability: Drug Development and Globalizing 
Clinical Trials, 32 AM. ETHNOLOGIST 183 (2005). 
 54. Id.; See also Jennifer Kahn, A Nation of Guinea Pigs, WIRED, Mar. 2006, available at 
http://www.wired.com/wired/archive/14.03/indiadrug.html. 
 55. Id. 
 56. Wai Lang Chu, Clinical Outsourcing Drags Big Pharma Out of Doldrums, 
DRUGRESEARCHER.COM, May 11, 2006, 
http://www.drugresearcher.com/news/ng.asp?n=67643-tufts-outsourcing-clinical-trials. 
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In the aftermath of the adoption of ICH E5 in 1998, a new variant of this 
industry emerged – CROs dedicated to conducting bridging studies, largely 
focused on gaining entry to the Japanese pharmaceutical market.  Thus, for 
example, Focus Clinical Drug Development (Focus), a CRO that split from 
SmithKline Beecham in 1992, has developed a specialized service in bridging 
studies which it advertises as providing “studies in healthy Japanese volunteers 
outside Japan.”57  Focus notes that “[p]hase I studies involving both Japanese and 
White volunteers are a key element for a rapid global drug development 
strategy,”58 and asserts that it “can provide pharmaceutical and biotech companies 
a more efficient way to conduct ICH-E5 compliant bridging studies outside 
Japan.”59  Focus offers standing “panels” of “440 Healthy Japanese volunteers 
(male/female)”60 most of whom are students in Europe, and “4,400 Healthy White 
Volunteers (male/female)”61 who it defines as “people with origin in Europe 
(including the western part of Russia), North Africa or Middle East.”62  These 
panels recapitulate the problematic ethnic/racial categories underlying the ICH E5 
and present the same problems discussed above.63  Nonetheless, Focus emphasizes 
that “[o]ur experience shows that Phase I bridging studies can be conducted 
outside Japan and based on our expertise are acceptable to the Japanese 
authorities.”64  The concentration on “White” and “Japanese” panels is not 
incidental.  ICH E5 and bridging studies are designed primarily to provide an 
avenue for Western pharmaceutical corporations to gain access to the lucrative 
Japanese market which hitherto had used concerns about ethnic variation in drug 
response as a non-economic barrier to trade. 
Similarly, Richmond Pharmacology bills itself as the “largest provider of 
Japanese/Caucasian bridging studies in Europe.”65  Clients of Richmond’s bridging 
studies include “US and European companies that want to launch into the Japanese 
 
 57. Focus Clinical Drug Development, Bridging Studies, http://www.bridgingstudies.de/ (last 
visited Sept. 20, 2006). 
 58. Focus Clinical Development, Introduction: Bridging Studies, 
http://www.bridgingstudies.de/html/bridgingstudies.html (last visited Sept. 20, 2006). 
 59. Id. 
 60. Focus Clinical Development, Panels and Recruitment, 
http://www.bridgingstudies.de/html/panel.html (last visited Sept. 20, 2006). 
 61. Id. 
 62. Id. 
 63. See supra text accompanying notes 41-51. 
 64. Focus Clinical Development, Our Offer, http://www.bridgingstudies.de/html/offer.html 
(last visited Sept. 20, 2006). 
 65. Bridging Studies from Richmond Pharmacology, Ltd., Welcome, 
http://www.bridgingstudies.com/ (last visited Sept. 20, 2006). 
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pharmaceutical market.”66  Richmond boasts “a dedicated in-house Japanese 
recruitment department, supported by a specialized marketing strategy and the 
bespoke brand trials4japanese.  Through this innovative approach, we receive circa 
250 enquiries per month from potential Japanese volunteers.”67 
These CROs construct their bridging studies around a presumption of intrinsic 
difference between the “Japanese” and “White” or “Caucasian” members of their 
human subjects panels.  Such studies have provided the basis for successful drug 
applications to Japanese regulatory authorities.  Ironically, however, Chikayuki 
Naito, Counselor to the Tokyo Teishin Hospital and Technical Advisor to the 
Japanese Organization for Pharmaceutical Safety and Research, has noted that 
intrinsic differences in drug response are likely nowhere near as significant as 
extrinsic factors such as medical practice.68 
Studies of the early effects of ICH E5 published in 2002 by CMR International, 
(which describes itself as “the foremost provider of R&D performance metrics to 
the global pharmaceutical industry”69)  found “little effect on the number of trials 
conducted in the EU and US,”70 but also indicated an industry-wide belief that ICH 
E5 was expected to have “positive effects in terms of reducing the number of 
patients required for trials conducted in Japan,”71 and would “lead to a reduction in 
costs and development times for new drugs.”72  One of the CMR studies noted that 
until the introduction of ICH E5 “repeat clinical trials were a fact of life in drug 
development if a company wished to market a drug in more than one ICH 
region.”73  ICH E5 marked a turning point in global drug development with Pfizer 
gaining approval of Viagra® in Japan less than a year after the guideline was 
finalized.74  Between 1999 and 2003, with Viagra leading the way, twenty new 
drug applications were approved in Japan based on bridging studies and an 
 
 66. Bridging Studies from Richmond Pharamcology, Ltd., Who We Work With, 
http://www.bridgingstudies.com/who/ (last visited Sept. 20, 2006). 
 67. Bridging Studies from Richmond Pharamcology, Ltd., Volunteer Panels, 
http://www.bridgingstudies.com/volunteers/ (last visited Sept. 20, 2006). 
 68. Chikayuki Naito, Necessity and Requirements of Bridging Studies and Their Present Status 
in Japan, 38 INT’L J. CLINICAL PHARMACOL. & THER. 80, 80-81 (2000). 
 69. CMR International, Home: About Us, http://www.cmr.org/ (last visited Sept. 20, 2006). 
 70. Carly Anderson, Neil McAulsane & Stuart Walker, R&D Briefing No. 36:  The Impact of 
the ICH E5 Guideline on Global Drug Development, 36 CMR INT’L 1, 5 (2002), available 
at http://www.cmr.org/pdf/r_d36.pdf. 
 71. Anderson and Kermani, supra note 23. 
 72. Id. 
 73. Id. 
 74. Id. 
PP 34-56 KAHN (AA) 12/9/2006  11:25 AM 
5 SANTA CLARA JOURNAL OF INTERNATIONAL LAW 1 (2006)  
  
46 
additional twenty-four were approved using important foreign data as references, 
leading one study to conclude that “the bridging strategy is becoming a common 
and practical basis for the decision making of marketing approvals of new drugs in 
Japan.”75  Another 2002 study of the ICH E5 noted that its “impact has been felt 
particularly in Japan, but as the E5 bridging strategies develop, the positive impact 
will be felt over a wide area in Pan-Asia and beyond to the rest of the world.”76 
IV.  The FDA Guidelines 
In January 2003, the FDA announced the promulgation of a Draft Guidance for 
Industry on the Collection of Race and Ethnicity Data for Clinical Trials for FDA 
Regulated Products.77  After notice and comments, the FDA issued the final 
guidance September, 2005.78  Before discussing the Guidance in detail, it is 
important to note that it emerged out of a longstanding concern to produce better 
data that would address the very real problem of health disparities in the United 
States.  Prominent federal mandates leading up the Guidance include the NIH 
Revitalization Act of 1993, which directed the NIH to develop guidelines for 
including women and minorities in NIH-sponsored clinical research,79 and the 
Food and Drug Modernization Act of 1997 (FDMA) which directed the FDA to 
examine issues related to the inclusion of racial and ethnic groups in clinical trials 
of new drugs.80  The FDMA led to the promulgation of the FDA Guidance and the 
NIH has also issued detailed guidelines and guidance mandating certain procedures 
and practices concerning the inclusion of ethnic and racial minorities in clinical 
trials.81 
Thus, for example, the NIH “Policy on Reporting Race and Ethnicity Data” 
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states, inter alia, that, the “NIH requires all grants, contracts, and intramural 
projects conducting clinical research to address the Inclusion of Women and 
Minorities. . . . Investigators are instructed to provide plans for the total number of 
subjects proposed for the study and to provide the distribution by ethnic/racial 
categories and sex/gender.”82  Similarly, the FDA recommends that individuals or 
corporations submitting drug approval applications use “a standardized approach 
for collecting and reporting race and ethnicity information in clinical trials 
conducted in the United States and abroad for certain FDA regulated products.”83 
As any federally funded researcher knows, these mandates impose significant 
requirements and provide incentives to identify and collect research data according 
to categories of race and ethnicity. 
The federally mandated racial and ethnic categories, however, are not 
biomedical in origin; rather they derive from the Office of Management and 
Budget’s (OMB) 1997 “Revisions to the Standards for the Classification of Federal 
Data on Race and Ethnicity.”84  These standards set forth “five minimum 
categories for data on race: American Indian or Alaska Native, Asian, Black or 
African American, Native Hawaiian or Other Pacific Islander, and White.”85  
There are “two categories for data on ethnicity: ‘Hispanic or Latino,’ and ‘Not 
Hispanic or Latino.’”86 These categories provide the basis for the classification of 
all federal data on race and ethnicity, most notably, the census. 
The OMB Standards, however, contain an important caveat: “The racial and 
ethnic categories set forth in the standards should not be interpreted as being 
primarily biological or genetic in reference.” 87  These categories were developed to 
serve social, cultural, and political purposes.  When the federal government 
requires biomedical researchers and clinicians to import these social categories into 
explicitly biological and/or genetic contexts, it is creating a structural situation in 
which social categories of race and ethnicity may easily become confused and 
conflated with biological and genetic categories in day to day practice. 
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In a “Talk Paper” discussing the issuance of the Draft Guidance in 2003, the 
FDA elaborated upon their nature and purpose: 
FDA regulations require drug sponsors to present an analysis of data according to age, 
gender and race. An analysis of modifications of dose or dosage intervals for specific 
groups is also required when manufacturers submit a new drug application for approval by 
FDA. To accomplish this, FDA recommends that the drug manufacturers use the OMB 
race and ethnicity categories during clinical trial data collection to ensure consistency in 
evaluating potential differences in drug response among racial and ethnic groups.88 
Consistency is a key theme throughout the Draft Guidance.  It exhibits a general 
concern to regularize the collection and submission of data on race and ethnicity 
across the spectrum of clinical trials and the drug development process.  The Draft 
Guidance specifically recommends the use of the OMB categories of race and 
ethnicity, first, to “help ensure consistency in demographic subset analyses across 
studies,” and second to help evaluate “potential differences in the safety and 
efficacy of pharmaceutical products among population groups.”89  The Guidance 
elaborates the rationale for this concern by referencing some studies that show on 
average members of certain OMB racial groups may respond differently to certain 
drug than members of other OMB racial groups.90  That is, the Guidelines connect 
race and physiology.  This in itself is highly problematic, as discussed above in 
reference to the ICH E5 definition of race.91 
The FDA Guidance contains the OMB caveat that its racial and ethnic 
categories are not to be interpreted as biological or genetic, but its 
recommendations, being based on physiological processes, nonetheless exist in 
tension with it.  This tension was recognized and seized upon by many 
pharmaceutical companies in offering comments to the Draft Guidelines in 2003.  
The response of pharmaceutical companies, however, was not uniform.  Large 
pharmaceutical companies with global marketing concerns focused in particular on 
inconsistencies between the FDA mandated use of the distinctively American 
OMB categories of race and ethnicity (e.g. “African American,” “Hispanic”) and 
those used internationally in other ICH regions.92  Their comments tended to call 
for a more sophisticated use of population categories that could be more easily 
integrated with the structure of ICH E5 and more readily translatable across 
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regions.93  Smaller biotechnology companies tended to be less concerned with the 
international ramifications of the Guidance but rather urged the adoption of new 
genetic technologies to provide more precise population categories for the 
collection of data.94 
Generally speaking, comments submitted by pharmaceutical corporations 
expressed concern over (1) inconsistent definitions of race and ethnicity, (2) 
questionable accuracy of definitions of race and ethnicity, (3) the negative impact 
that using OMB categories of race and ethnicity might have on global trial 
recruitment, and (4) the creation of unnecessary and unscientific differences 
among populations through the use of inappropriate racial and ethnic categories.  
Underlying the concerns of large pharmaceutical corporations in particular was a 
perceived need to develop a globally applicable standard for the collection of racial 
and ethnic data – clearly more inline with the mandate of ICH E5.  In short, where 
the ethnic categorizations of ICH E5 were perceived as opening up global markets, 
the OMB-based racial and ethnic classifications of the FDA Guidance were 
perceived as a potential barrier to globalization of drug markets. 
A.  Inconsistent Definitions 
The Pharmaceutical Research and Manufacturers of America (PrHMA) 
describes itself as representing “the country’s leading pharmaceutical research and 
biotechnology companies, which are devoted to inventing medicines that allow 
patients to live longer, healthier, and more productive lives.”95 It opened its 
comments to the FDA Draft Guidance with an admonition that “for these 
categories to be valuable globally and to permit identification of ethnic differences, 
there should be only one set of agreed ethnic/racial categories.”96  It therefore 
recommended that the issue be brought to the ICH as a forum for the development 
of globally consistent categories.97  Comments submitted by Pharmacia98 
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(subsequently acquired by Pfizer) largely replicated comments submitted by 
PhRMA, and focused in particular on the myriad ways in which the Guidance 
threatened to obstruct pharmaceutical globalization.  With regard to inconsistent 
definitions of race and ethnicity, Pharmacia observed that, 
The OMB race and ethnicity categories can be used only in the US, not in the EU or in 
Japan; this is especially true for the ethnicity questions (Hispanic/Latino vs. Not 
Hispanic/Latino). A definition of the ethnicity varies among the ICH countries, as well as 
non-ICH countries. There will be more opportunities for the US to utilize foreign clinical 
data in evaluating safety and efficacy of new drugs in the future. Therefore, it is 
recommended that the race and ethnicity categories should be more scientific and globally 
accepted so that the data comparison becomes more meaningful and provides valuable 
information in evaluating potential differences or similarities in safety and efficacy of new 
drugs among population subgroups.99 
There is a clear recognition here that the OMB definitions of race and ethnicity 
are not static, scientifically objective categories.  Pharmacia (and PhRMA) is 
concerned that imposing the US regulatory definitions of race on the 
pharmaceutical industry will inhibit the globalization of pharmaceutical markets.  
Its comments explicitly reference the ICH and later employ the E5’s distinction 
between intrinsic and extrinsic factors in evaluating the significance of race and 
ethnicity in drug development.100  Ironically, though, the comments also assume 
that it will be somehow possible to develop categories of race and ethnicity that are 
“more scientifically and globally accepted.”  The key focus here seems really to be 
on global acceptance – hence the reference to the ICH structure.  Comments 
submitted by Abbot Laboratories expressed a similar concern that the OMB 
categories were “oversimplified” and “vague,” and urged that the FDA 
“recommend a better definition of race and ethnicity that can be understood by a 
subject in a study and be consistent across the board.”101  Bristol-Meyers Squibb 
also noted that the Guidance’s “proposed ethnicity and racial categories may be 
understood differently in different parts of the world,” and urged the development 
of “better defined categories.”102  Thus, for example, it proposed that the OMB 
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category of “Black or African American” be revised to “Black, of African heritage 
or African American.”103  Given the OMB’s own caveat that its categories are not 
genetic or biological, the clear concern is such a proposal is not to present a more 
“scientific” definition of race but rather to produce a more globally acceptable 
definition.  The two are not necessarily the same. 
Of all the OMB categories incorporated in the Guidance’s mandate, the 
ethnicity category of “Hispanic or Latino” caused particular concern in terms of 
consistent global application. Bristol Meyers Squibb noted that, “the requirement 
that Hispanic or Latino versus not Hispanic or Latino ethnicity be collected even in 
trials that are conducted entirely outside the US seems contradictory to the spirit of 
the ICH guidelines. If ethnicity designations, as per the guidance, are to reflect the 
sociocultural construct of the society, then the proposed category is generally 
inappropriate outside the United States.”104 Again, there is a patent concern for 
potential conflict with the ICH E5 guidelines and resulting barriers to the efficient 
globalization of markets. 
B.  Questionable Accuracy 
The asserted inappropriateness of the Latino/Hispanic category in a global context 
was also used to highlight the questionable accuracy of the Guidance’s 
terminology.  Thus, Pharmacia argued that “[t]he terms Hispanic and Latino will 
not have the same meaning outside the U.S. as they do within the U.S. According 
to the definition, Spaniards are considered Hispanic, but they are both culturally 
and racially more similar to French than Mexicans.”105 
 Similarly, Bristol Meyers Squibb notes that, “terminology – like ‘Latino’ – 
can be confusing outside the United States, while the medical relevance of such 
category is not demonstrated inside the US.”106  Pharmacia goes on to make similar 
criticisms of the accuracy of the OMB categories noting that “there is no 
distinction among the Asian group, which may be more genetically variable.”107 In 
mentioning similarity and difference, medical relevance, and genetic variability, 
these comments go beyond the earlier stated concern for globally consistent 
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definitions to the basic scientific accuracy of the categories themselves.  And yet, 
after these criticisms, the corporations do not call upon the FDA to reject such 
classificatory schemes as inherently lacking “medical relevance” for drug 
development, but rather simply suggests developing more globally applicable, 
uniformly adoptable ethnic and racial categories – categories, in short, whose 
primary purpose is to serve efficient globalization rather than accurate science. 
Significantly, however, smaller biotechnology companies specializing in 
genetic research urged a different approach to overcoming similar problems of 
definitional accuracy.  These companies, notably Genaissance Pharmaceuticals and 
DNAPrint Genomics do not have the global reach of corporations such as 
Pharmacia or Bristol Meyers Squibb.  Genaissance, for example, describes itself as 
“a biotechnology company whose business is based on the discovery of human 
gene variation for the development of personalized medicines.”108  It markets its 
technology to large pharmaceutical corporations rather than engaging directly in 
global drug development and marketing.109  The focus of their criticisms of the 
FDA Guidance, therefore, was less on developing globally consistent categories of 
race and ethnicity, and more on using their own proprietary genetic technologies to 
provide purportedly more scientifically objective and accurate definitions of race 
and ethnicity. 
In its comments on the OMB Categories employed by the Draft Guidance, 
Genaissance focused on genetic accuracy, observing that, 
Although these categories may be useful for national demographics, they are substandard 
with regard to the state-of-the-art in genetic analysis of ancestry. In a population such as 
the United States that increasingly is mixed, the boundaries between these classifications 
are likely to be blurred further. For example, Genaissance has conducted genetic analysis 
of Hispanic populations from Florida and California. It is very clear that the label 
“Hispanic” encompasses individuals with African descent and Native American descent, 
as well as Caucasian descent.110 
Genaissance here very subtly introduces the concept of genetic ancestry as a 
metric to assess the validity of the OMB categories of race and ethnicity.  In 
speaking of blurring and mixing, the comment implies that there are some 
underlying genetically pure categories of “Caucasian,” “African,” and “Native 
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American” – a very problematic assertion.  Moreover, focusing, like many other 
comments, on the term “Hispanic” as mixed and blurred, it sets forth a straw man.  
It is precisely because of the lack of conceptual congruence between the term 
Hispanic/Latino and terms such as African, Caucasian, and Native American that 
the OMB separated out ethnic from racial categories. 
Nonetheless, Genaissance recognizes the questionable accuracy of using any 
racial or ethnic categories in the context of pharmaceutical research and 
development.  Commenting on the Draft Guidance’s discussion of the relation 
between race and drug metabolism, Genaissance notes that, “the link between 
these clinical outcomes and race is anecdotal at best and discriminatory at worst.  
New genetic technologies offer much more precise relationships between the 
genotype of an individual and the clinical management of disease.”111  Genaissance 
presents a solution to this problem in the form of its proprietary technology which 
it asserts “would afford a high-resolution genetic identification of ancestry, 
consistent analysis of ethno-geographic backgrounds, and possible use directly to 
diagnostics for improvement of drug therapy.”112  That is, it urges the FDA to 
replace OMB categories of race with genetic categories of ancestry, recommending 
“the adoption of new genetic systems for ancestry determination rather than 
antiquated and potentially inaccurate racial denominations.”113  Unlike the 
suggestions from large pharmaceutical corporations, Genaissance here is less 
concerned with global uniformity per se and more with the purported scientific 
accuracy of the categories – accuracy to be provided by its own technology.  One 
basic problem with Genaissance’s claim to more rigorous scientifically based 
categories of ancestry is that its own discussion of them is premised on definitions 
of ancestral population that essentially replicate the OMB categories.  Thus, in 
discussing its genetic analysis of samples from US populations, it groups the 
samples as “African American, Asian, Caucasian, and Hispanic/Latino.”114 
In a similar vein, the comments from DNAPrint Genomics (which describes 
itself as “an applied science company focused on the development and marketing 
of innovative genetic testing products and services,”115) urge that “for the sake of 
science and the health of us all . . . it is time to incorporate molecular 
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anthropological data metrics”116 to supplement the OMB categories in the 
collection of racial and ethnic data for clinical trials.  It argues that its own 
proprietary genetic concept of “Biogeographical Ancestry”117 (BGA) is better 
suited for evaluating drug response than the OMB categories of race and ethnicity.  
Like Genaissance, DNAPrint emphasizes the lack of accuracy inherent in self-
reporting of race and suggests “that the FDA should pay more attention to 
molecular characterization of population structure when evaluating and assisting 
with the construction of clinical trials.” 118 
Ironically, the genetic approaches taken by Genaissance and DNAPrint comport 
well with ICH E5’s own categorization of race as an intrinsic genetic factor.  
However the genetic approaches also suffer from the same dangers and 
inaccuracies as the ICH E5 definition as discussed above,119 despite the patina of 
scientific rigor layered upon them in the comments.  In the end, where big 
pharmaceutical corporations simply want to regularize race and ethnic categories 
in whatever form they take so as to facilitate global drug development, small 
biotech companies want to take control of the actual process of racial and ethnic 
categorization and transform it into a function of genetics. 
C.  Negative Impact on Global Trial Recruitment 
Beyond inconsistency and inaccuracy, large pharmaceutical companies also 
expressed a pragmatic concern that being required to collect data according to the 
OMB categories could have a significant detrimental impact on their ability to 
recruit human subjects for clinical trials in a global environment.  Here again, the 
category of Hispanic/Latino was of particular concern.  Pharmacia addressed this 
issue most directly, noting that 
Asking subjects about their race/ethnicity may be very sensitive in many circumstances 
and could be viewed as a bureaucratic burden.  Conducting a study in Japan, e.g., and 
asking a subject whether they are Hispanic may result in patients taking questionnaires less 
seriously and compromising other data being collected. 120 
The specific reference to Japan echoes discussions surrounding the adoption of 
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ICH E5 regarding the need to open up Japanese markets to Western 
pharmaceuticals.  Companies wishing to conduct bridging studies in Japan in 
accordance with the ICH E5 guidelines certainly would not want their efforts 
complicated or even subverted by the dictates of the FDA Guidance.  Recruiting 
human subjects for clinical trials is difficult under the best of circumstances.  In a 
commercial environment where ever increasing numbers of clinical trials are being 
outsourced to countries around the world, Pharmacia here recognizes that the 
regulatory construction of race and ethnicity may pose as great a barrier to the 
globalization of markets as the medical construction of racial and ethnic difference 
that underlay Japanese barriers to the approval of Western pharmaceuticals. 
D.  The Creation of Unnecessary and Unscientific Difference 
Many of the comments, as discussed above, challenge the accuracy and 
consistency of the OMB categories as a basis for collecting clinical data.  An 
important subset of these concerns was a recognition by both Pharmacia121 and 
PhRMA122 that using the social categories of the OMB in the context of drug 
development might lead to the creation of the perception of relevant differences 
where in fact none existed.  Such differences would present unnecessary barriers to 
global drug development.  Pharmacia noted that: 
The first paragraph [of the Draft Guidance] states that the categories are not based on 
scientific principles. It is understandable that the U.S. government wants to sort issues by 
various socio/cultural groups. However, if there is no scientific basis for examining the 
effects (either positive or negative) in these groups, doing so may provide an opportunity 
for identifying differences where none exist.  Collecting the data by these definitions is 
one thing, using it to distinguish effects in different populations is another.123 
Pharmacia here recognizes that racial and ethnic data is a double edged sword.  
While it may be used to open up Japanese markets, it also may be misused and 
misinterpreted in a manner that obstructs markets.  Once again, the OMB 
categories are criticized as barriers to globalization.  And yet, in all of this, the 
calls for uniform globally applicable standards of race and ethnicity bring us back 
to the ICH E5 Guidelines which characterize race as an intrinsic genetic attribute – 
with all the problems and dangers that entails. 
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V.  Conclusion — Harmonizing Race 
The FDA responded to the comments124 and issued its final Guidance125 in 
September, 2005.  The final Guidance remained substantially the same as the 
Draft.  Among the significant revisions was added text that allowed the omission 
of the characterization of Hispanic or Latino for international clinical trials, and a 
change in the characterization of “Black, of African Heritage,” to “Black” for 
studies conducted abroad.126  The Guidance continues to recommend the use of the 
OMB categories when collecting data – even for studies conducted outside the 
United States, but recognizes that “these categories may not adequately describe 
racial and ethnic groups in foreign countries.”127  The FDA, therefore, does seem 
to have been at least somewhat responsive to the concerns expressed by large 
pharmaceutical companies that the categories not impede global research, 
development and marketing.  Nonetheless, the final Guidance makes no concession 
toward the suggestions to adopt purportedly more genetically based classifications 
of ancestry proposed by Genaissance and DNAPrint. 
The story of ICH E5 and the FDA Guidelines reveals the complexity of 
navigating distinct regulatory regimes in the context of increasingly globalized 
drug markets.  It points up the enduring conceptual power of race and ethnicity to 
shape understandings of human populations in diverse venues.  Of greatest 
concern, perhaps, is that the drive to harmonize race also threatens to geneticize 
race.  Throughout this story, race and ethnicity are presented largely as barriers to 
globalization – differences that need to be somehow overcome in order for markets 
to grow.  Harmonization, both as an explicit concern of the ICH and as the 
unavoidable backdrop to the FDA Guidance, is providing the impetus to produce 
regular, standardized categories of race and ethnicity.  In both ICH E5 and in the 
discussions surrounding the FDA Guidance, a prominent attribute of calls for 
harmonization has been an appeal to genetics – whether as an “intrinsic” aspect of 
race or as a component of “Biogeographical Ancestry.”  These purportedly more 
objective or scientific understandings of race and ethnicity as a function of genetics 
are proposed as a means to stabilize the inconsistency of social categories and 
provide a basis for unifying global markets.  In the drive to harmonize international 
drug development we must be careful to avoid adopting a harmonized conception 
of race as genetic. 
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